Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

NCT04444921 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04444921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04444921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 17, 2020
Completion date
March 31, 2027
Enrollment
205 (estimated)
Sites
579

Conditions

As the registry lists them; a condition with its own page is linked.

anal basaloid carcinoma, anal canal cloacogenic carcinoma, metastatic anal squamous cell carcinoma, recurrent anal squamous cell carcinoma, stage iii anal cancer ajcc v8, stage iv anal cancer ajcc v8, unresectable anal squamous cell carcinoma